NEOLEUKIN THERAPEUTICS, INC.
360-1616 Eastlake Avenue East
Seattle, Washington 98102
December 17, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Margaret Schwartz Office of Life Sciences | |
| Re: | Neoleukin Therapeutics, Inc. Registration Statement on Form S-3 Filed December 11, 2020 File No. 333-251294 | |
Via EDGAR—Acceleration Request
Requested Date: December 21, 2020
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Neoleukin Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| NEOLEUKIN THERAPEUTICS, INC. | ||
| By: | /s/ Robert Ho | |
| Robert Ho | ||
| Chief Financial Officer | ||
| cc: | Jonathan Drachman, Chief Executive Officer Holly Vance, General Counsel Neoleukin Therapeutics, Inc.
Robert Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP |